Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit?

Nephrology Dialysis Transplantation

Volumn 24, Issue 1, 2009, Pages 21-27

  Sommerer, Claudia ^a,b   Giese, Thomas ^b   Meuer, Stefan ^b   Zeier, Martin ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Calcineurin inhibitor; Pharmacodynamic; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CALCINEURIN; CALCINEURIN INHIBITOR; CYTOKINE; GAMMA INTERFERON; HLA ANTIBODY; INTERLEUKIN 2;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EXPOSURE; DRUG INHIBITION; DRUG MONITORING; GENE EXPRESSION; HUMAN; KIDNEY GRAFT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR;

CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MODELS, IMMUNOLOGICAL; TACROLIMUS;

EID: 58049219003     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn556     Document Type: Review

References (74)

1. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
2. Pirsch JD, Miller J, Deierhoi MH et al. FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983
3. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565
4. Sommerer C, Hergesell O, Nahm AM et al. Cyclosporin A toxicity of the renal allograft - a late complication and potentially reversible. Nephron 2002; 92: 339-345
5. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney - graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628
6. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-1588
7. Meier M, Nitschke M, Weidtmann B et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81: 1035-1040
8. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738
9. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606
10. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002; 24: 40-46
11. 2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003; 76: 1236-1238
12. 2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 2004; 19: 215-222
13. Keown P, Cole E, Muirhead N et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulson in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744-1752
14. International Neoral Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156
15. Mahalati K, Belitsky P, Sketris I et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62
16. Morris RG, Russ GR, Cervelli MJ et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486
17. 2) levels: which one is a predictor of graft loss? Transplant Proc 2007; 39: 1223-1224
18. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828-833
19. Büchler M, Chadban S, Cole E et al. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phase. Nephrol Dial Transplant 2006; 21: 197-202
20. 2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. Bio Drugs 2001; 15: 279-290
21. 2 monitoring in long-term renal transplant recipients receiving cyclosporinemicroemulsion. Transplantation 2005; 79: 802-806
22. 2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577-583
23. 2 monitoring: an international consensus statement. Transplantation 2002; 73: S12-S18
24. 2 monitoring: a European consensus. Transplant Int 2005; 18: 768-778
25. Balbontin F, Kiberd B, Singh D et al. Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation. Transplant Proc 2003; 35: 2409-2411
26. 2 level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience. Transplant Proc 2001; 33: 3098-3099
27. 0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006; 28: 637-642
28. 2-level monitoring: a systematic review. Transplantation 2007; 83: 1525-1535
29. Oellerich M, Barten MJ, Armstrong VW. Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit 2006; 28: 35-38
30. Barten MJ, Dhein S, Chang H et al. Assessment of immunosuppressive drug interaction: inhibition of lymphocyte function in peripheral human blood. J Immunol Methods 2003; 283: 99-114
31. Stalder M, Birsan T, Holm B et al. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit 2003; 25: 22-27
32. Flores MG, Zhang S, Ha A et al. In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCRas two independent and correlated read-outs. J Immunol Methods 2004; 289: 123-135
33. Chang DM, Ding YA, Kuo SY et al. Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol Invest 1996; 25: 13-21
34. Speiser DE, Loliger CC, Siren MK et al. Pre-transplant cytotoxic donor T-cell activity specific to patient HLA class I antigens correlating with mortality after unrelated BMT. Br J Haematol 1996; 93: 935-939
35. van Besouw NM, Van Der Mast BJ, de KP et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70: 136-143
36. Steinmann J, Kaden J, May G et al. Failure of in vitro T-cell assays to predict clinical outcome after human kidney transplantation. J Clin Lab Anal 1994; 8: 137-162
37. Weimer R, Melk A, Daniel V et al. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol 2000; 61: 884-887
38. Beimler JH, Süsal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 2006; 20: 7-12
39. Süsal C, Pelzl S, Döhler B et al. Identification of highly responsive kidney transplant recipients using pre-transplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650-1656
40. Weimer R, Süsal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transpl 2006; 6: 1865-1874
41. Kowalski RJ, Post DR, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88
42. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82: 663-668
43. Cadillo-Chavez R, de Echegaray S, Santiago-Delphin EA et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006; 38: 918-920
44. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697
45. Halloran PF, Helms LM, Kung L et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361
46. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of the cyclosporine effect. Clin Chem 1999; 45: 1477-1484
47. Hartel C, Fricke L, Schumacher N et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte co-stimulation: a quantitative measure of the efficacy of cyclosporine A-based immunosuppression. Clin Chem 2002; 48: 2225-2231
48. Hartel C, Schumacher N, Fricke L et al. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem 2004; 50: 141-151
49. Fruman DA, Klee CB, Bierer BE et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686-3690
50. Piccinini G, Gaspari F, Signorini O et al. Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Transplantation 1996; 61: 1526-1531
51. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant 2002; 2: 173-178
52. Batiuk TD, Pazderka F, Halloran P. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995; 59: 1400-1404
53. Grinyo JM, Cruzado JM, Millan O et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 2004; 78: 1400-1403
54. Caruso R, Perico N, Cattaneo D et al. Whole-blood clacineurin activity is not predicted by cyclosporine blood concentration in renal transplant patients. Clin Chem 2001; 47: 1679-1687
55. Blanchet B, Hulin A, Duvoux C et al. Determination of serine/threonine protein phosphatase type 2B (PP2B) in lymphocytes by HPLC. Anal Biochem 2003; 312: 1-6
56. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem 2004; 50: 2331-2337
57. Sellar KJ, van Rossum HH, Romijn FPHT et al. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. Anal Biochem 2006; 358: 104-110
58. Millan O, Brunet M, Campistol JM et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003; 49: 1891-1899
59. van Rossum HH, Romijn FP, Sellar KJ et al. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin Chem 2008; 54: 517-524
60. Rostaing L, Puyoo O, Tkaczuk J et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 400-409
61. Bohler T, Nolting J, Kamar N et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 2007; 29: 77-86
62. Barten MJ, Tarnok A, Garbade J et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007; 40: 50-63
63. Fitzpatrick DR, Kelso A. Independent regulation of cytokine genes in T cells. Transplantation 1998; 65: 1-5
64. Strehlau J, Pavlakis M, Lipman M et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700
65. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004; 19: S55-S60
66. Giese T, Zeier M, Schemmer P et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339-344
67. Sommerer C, Konstandin M, Dengler T et al. Pharmacodynamic- monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280-1285
68. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003; 57: 93-98
69. Pai SY, Fruman DA, Leong T et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994; 84: 3974-3979
70. Sanquer S, Schwarzinger M, Maury S et al. Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation. Transplantation 2004; 77: 854-858
71. Fukudo M, Yano I, Masuda S et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005; 78: 168-181
72. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007; 20: 1036-1043
73. Sommerer C, Hartschuh W, Enk A et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22: 549-554
74. Sommerer C, Giese T, Schmidt J et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008; 85: 15-21